EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CRISPR/Cas9-Based Modeling of JAK2 V617F Mutation in K562 Cells Reveals Enhanced Proliferation and Sensitivity to Therapeutic Agents

Nungruthai Nilsri, Rujira Mekchaaum, Supaporn Kalasin, Jirapas Jongjitwimol iD, Krai Daowtak iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26104600 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Nungruthai Nilsri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Technology, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand. Hauptthemen laut MEDLINE: Janus Kinase 2, CRISPR-Cas Systems, Mutation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Naresuan University research funding and Faculty of Allied Health Sciences, Naresuan University research funding, Naresuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Janus kinase 2 (JAK2) protein fulfills an important role in hematopoiesis via the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, as it provides the genetic driver of BCR::ABL1-negative myeloproliferative neoplasms (MPNs), which are clinically manifested as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The most common cause of MPNs is the mutation of JAK2 V617F in the JAK2 gene, which results in increased cell proliferation. However, both the pathogenesis and treatment regimen of BCR::ABL1-negative MPNs remain poorly understood. The aim of the present study was to establish K562 cell lines with a point mutation in exon 14 (JAK2p.V617F) using CRISPR/Cas9 technology. The modified JAK2 V617F cell lines were examined for the gene mutation using droplet digital PCR (DDPCR), and the presence of the mutation was confirmed by DNA sequencing. Modified cells were characterized by measuring JAK2 gene expression and the extent of cell proliferation. Interferon α2a (IFN-α2a) and arsenic trioxide were also administered to the cells to explore their potential effects. The JAK2 V617F-mutated cells were found to exhibit a higher level of JAK2 gene expression compared with the wild type. Interestingly, a significant increase in the proliferation rate was observed with the modified cells compared with the wild type cells (p < 0.001), as assessed from the JAK2 gene expression levels. Furthermore, the treatments with IFN-α2a and arsenic trioxide led to the preferential suppression of the cell proliferation rate of the K562 expressing mutant JAK2 cells compared with the wild type cells, and this suppression occurred in a dose-dependent manner(p < 0.01). Moreover, the modified cells were able to differentiate into megakaryocyte-like cells following stimulation with phorbol 12 myristate 13 acetate (PMA). Taken together, the results of the present study have shown that the CRISPR/Cas9-modified JAK2 V617F model may be used as a disease model in the search of novel therapies for MPNs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2CRISPR-Cas SystemsMutationHumansCell ProliferationK562 CellsInterferon-alphaArsenic TrioxideMyeloproliferative DisordersAntineoplastic AgentsPoint Mutation

Stichwörter der Autor:innen

CRISPR/Cas9JAK2 V617F mutationarsenic trioxideinterferon α2a

Substanzen

Janus Kinase 2JAK2 protein, humanInterferon-alphaArsenic TrioxideAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Technology, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand.
  • Cellular and Molecular Immunology Research Unit, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand.

ORCID-Profile: Jirapas Jongjitwimol, Krai Daowtak

Förderung

  • Naresuan University research funding and Faculty of Allied Health Sciences, Naresuan University research funding
  • Naresuan University

Zitieren

APA

Nilsri, N., Mekchaaum, R., Kalasin, S., Jongjitwimol, J., & Daowtak, K. (2025). CRISPR/Cas9-Based Modeling of JAK2 V617F Mutation in K562 Cells Reveals Enhanced Proliferation and Sensitivity to Therapeutic Agents. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26104600

Vancouver

Nilsri N, Mekchaaum R, Kalasin S, Jongjitwimol J, Daowtak K. CRISPR/Cas9-Based Modeling of JAK2 V617F Mutation in K562 Cells Reveals Enhanced Proliferation and Sensitivity to Therapeutic Agents. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26104600

BibTeX
@article{Nilsri2025,
  author = {Nilsri, Nungruthai and Mekchaaum, Rujira and Kalasin, Supaporn and Jongjitwimol, Jirapas and Daowtak, Krai},
  title = {CRISPR/Cas9-Based Modeling of JAK2 V617F Mutation in K562 Cells Reveals Enhanced Proliferation and Sensitivity to Therapeutic Agents},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26104600}
}
Kostenlos starten →